Different Injection Number of the Same Dose of Botulinum Toxin A on Overactive Bladder Syndrome
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
Overactive bladder (OAB) is a symptom syndrome characterized by urgency frequency with or
without urge urinary incontinence (UUI) that may affect the patients' quality of life.
Current medical treatments are usually unsuccessful in completely eradicating urgency
sensation. Intra-detrusor injection of botulinum toxin A (BoNT-A) modulates the release of
neurotransmitters from sensory nerve endings and effectively modulates the inflammatory
process mediated by nociceptive afferent nerve dysfunction. Satisfactory clinical results
were achieved with intravesical BoNT-A injection, which increased bladder capacity and
decreased urgency sensation in patients with neurogenic or idiopathic detrusor overactivity
(NDO, IDO). Excellent results were achieved with injection of either 100 U or 200 U of
BoNT-A. Episodes of frequency, urgency, and UUI were reduced, maximal cystometric capacity
increased, maximal detrusor pressure (Pdet) decreased, and the quality of life index also
improved significantly. However, post void residual (PVR) volume increased significantly and
some patients required clean intermittent catheterization (CIC) to evacuate the PVR.
Dose-related adverse events (AE) increased with increasing dose of BoNT-A. Therefore,
adjustments of the BoNT-A dose and sites of injection might minimize the de novo AE and help
to maintain success rates.
Phase:
Phase 2
Details
Lead Sponsor:
Buddhist Tzu Chi General Hospital
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA